Build on insulin affordability reform

Access to insulin can be a matter of life or death for those with diabetes, a disease that more than 37 million Americans live with. But the drug’s soaring price can alarmingly put it out of reach of those who need it.

“The price of insulin has risen inexplicably over the past 20 years at a rate far higher than the rate of inflation,” according to an analysis published in Mayo Clinic Proceedings in 2020. “One vial of Humalog, which used to cost $21 in 1999, costs $332 in 2019, reflecting a price increase of more than 1000%.”

The cost of other drugs has risen during the same time, of course. Ideally, Congress would swiftly pass a remedy to ensure that all medications are affordable. But that isn’t realistic given deepening political divides and the even deeper pockets of pharmaceutical industry lobbyists.

What is doable is passing a targeted reform to help make insulin more affordable for those whose lives depend on it. This spring, there was laudable momentum to enact such a fix, with the U.S. House passing the Affordable Insulin Now Act championed by Rep. Angie Craig, a Minnesota Democrat.

The challenge now is to sustain that moment and ensure the Senate also acts on insulin affordability this year.

In 2017, a young Minnesotan’s death tragically spotlighted the nation’s insulin cost crisis. Alec Smith, 26, had just aged off his mother’s health plan. He couldn’t afford insulin and died after trying to ration it.

Minnesota legislators responded with compassionate common sense in 2020 when they passed the state’s pioneering emergency insulin assistance bill. Those who meet its reasonable eligibility guidelines can quickly get a 30-day supply for $35 from local pharmacies.

But access to this critical drug shouldn’t depend on where you live. That’s why federal reform covering all 50 states is so important.

Ms. Craig’s bill, if enacted, would cap insured individuals’ out-of-pocket insulin costs at $35 a month. A critical caveat: that price ceiling only applies to those with health insurance. It also doesn’t get at the root of soaring insulin costs.

This bill is not a panacea, Ms. Craig acknowledged. Nevertheless, it is still a strong step forward and would help many families struggling with insulin costs, which can be daunting even for those who have health insurance.

“The average commercial insurance plan in my district ... they’re paying up to $300 or $400 a month in copays for their insulin. So to be able to cap the out-of-pocket cost of insulin at $35 a month,” Ms. Craig said, would be “life-changing for people who have access to insurance.”

The Senate companion bill to Ms. Craig’s legislation likely faces an uphill battle in a closely divided chamber. An “insulin-only bill would need 60 votes to pass in the Senate, instead of a simple majority,” according to the Kaiser Family Foundation.

Other insulin cost reforms are under consideration in the Senate that could expand bipartisan support. Families struggling to afford insulin can’t wait. Action and bipartisanship are urgently needed.